AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (22:6n-3)
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:1n-7
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ5-desaturase
Number of subjects: 2448
Study 25123120 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 55
Study 25123851 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution (Axiron®), 60-mg daily morning dose applied to axillae (30 mg/axilla)
Number of subjects: 155
Study 25123851 — intervention group
Group type: COMPARATOR
Intervention: Single testosterone measurements
Number of subjects: 155
Study 25124284 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic Intracranial Atherosclerosis (ICAD) detected via MRI
Number of subjects: 200
Study 25124284 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco use
Number of subjects: 200
Study 25124284 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet
Number of subjects: 200
Study 25124284 — intervention group
Group type: EXPERIMENTAL
Intervention: High socioeconomic status
Number of subjects: 200
Study 25124284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 200
Study 25124284 — intervention group
Group type: COMPARATOR
Intervention: Age, gender, diabetes, hypertension, depression, and physical activity
Number of subjects: 200
Study 25125207 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Ace
Number of subjects: 14
Study 25125207 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Number of subjects: 14
Study 25125207 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 14
Study 25125207 — intervention group
Group type: EXPERIMENTAL
Intervention: Enseal
Number of subjects: 14
Study 25125294 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated contact force (CF)-sensing catheter
Number of subjects: 172
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervated myocardium
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervated myocardium > 37.6% of left ventricle (LV)
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-diastolic volume > 98 mL/m(2)
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine level > 1.49 mg/dL
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: No angiotensin-inhibition therapy
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of all four factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Number of subjects: 0
Study 25125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Number of subjects: 0
Study 25125973 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled pen (Metex(®) PEN/Metoject(®) PEN)
Number of subjects: 120
Study 25125973 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Injection Assessment Questionnaire (SIAQ)
Number of subjects: 120
Study 25125973 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe (Metex(®)/Metoject(®))
Number of subjects: 120
Study 25126038 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal index
Number of subjects: 133
Study 25126038 — intervention group
Group type: EXPERIMENTAL
Intervention: RCREC (respiratory cycle-related EEG changes)
Number of subjects: 133
Study 25126038 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral measures
Number of subjects: 133
Study 25126421 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MHP vaccine
Number of subjects: 23
Study 25126443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 24
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal capillary microvascular flow index (< 2.6)
Number of subjects: 501
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachycardia (heart rate > 90 beats/min)
Number of subjects: 501
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 501
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor use
Number of subjects: 501
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate level more than 1.5 mEq/L
Number of subjects: 501
Study 25126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal microvascular flow index in patients with tachycardia
Number of subjects: 501
Study 25127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid regimen with median dosing of 55 mg/m2/day, median cumulative dose of 3,440 mg/m2 for the first episode, median duration of 21 weeks.
Number of subjects: 231
Study 25127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment including albumin infusions, diuretics, and acetyl salicylic acid.
Number of subjects: 231
Study 25127973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT)
Number of subjects: 2046
Study 25128349 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF PET/CT
Number of subjects: 0
Study 25128349 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 0
Study 25128349 — intervention group
Group type: COMPARATOR
Intervention: NaF and FDG
Number of subjects: 0
Study 25129345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² every 3 weeks for four cycles
Number of subjects: 107
Study 25130920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide plus basal insulin
Number of subjects: 0
Study 25130920 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin alone
Number of subjects: 0
Study 25130947 — intervention group
Group type: EXPERIMENTAL
Intervention: 88 μg·kg(-1) of epinephrine (1:10,000) injected into the caudal epidural space
Number of subjects: 1
Study 25130947 — intervention group
Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 1
Study 25131866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel with prednisone/prednisolone
Number of subjects: 0
Study 25131866 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone with prednisone/prednisolone
Number of subjects: 0
Study 25131866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 25131866 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 0
Study 25132507 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vaccine
Number of subjects: 25
Study 25132507 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg vaccine
Number of subjects: 25
Study 25132507 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg vaccine
Number of subjects: 25
Study 25133198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1.2 g/day for 15 days/month for 2 months
Number of subjects: 40
Study 25133198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25133431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously for 84 days
Number of subjects: 10
Study 25133535 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 9
Study 25134640 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with total lung capacity (TLC) in COPD, specifically SNP rs114929486 on chromosome 5p15.2.
Number of subjects: 4543
Study 25135035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (100, 150, 300, or 600 mg/day)
Number of subjects: 152
Study 25135035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 25135035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 152
Study 25135178 — intervention group
Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program step 1 diet plus pravastatin (n=3866)
Number of subjects: 7832
Study 25135178 — intervention group
Group type: COMPARATOR
Intervention: National Cholesterol Education Program step 1 diet alone (n=3966)
Number of subjects: 7832
Study 25135178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diet-alone and diet-plus-pravastatin groups
Number of subjects: 7832
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid renal perfusion
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Left heart bypass
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic visceral perfusion
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific surgical adjuncts (endarterectomy, open stent placement)
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall operative mortality
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty-day survival
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ischemia
Number of subjects: 1267
Study 25135232 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent II and III TAAA repairs
Number of subjects: 1267
Study 25135443 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™)
Number of subjects: 69
Study 25135992 — intervention group
Group type: EXPERIMENTAL
Intervention: R2CHOP (lenalidomide 25 mg orally per day on days 1-10 combined with standard-dose R-CHOP every 21 days for six cycles)
Number of subjects: 64
Study 25135992 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (control group from Lymphoma Database)
Number of subjects: 64
Study 25135992 — intervention group
Group type: EXPERIMENTAL
Intervention: R2CHOP
Number of subjects: 64
Study 25135998 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin administered sequentially with CHOP
Number of subjects: 26
Study 25135998 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg plus CHP (BV+CHP)
Number of subjects: 26
Study 25135998 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin administered sequentially with CHOP or in combination with CHP
Number of subjects: 26
Study 25136024 — intervention group
Group type: COMPARATOR
Intervention: Tedizolid phosphate 200 mg (single oral dose for hepatic impairment, intravenous for renal impairment); hemodialysis subjects received two doses (separated by 7 days) before and after dialysis.
Number of subjects: 0
Study 25136024 — intervention group
Group type: COMPARATOR
Intervention: Tedizolid phosphate 200 mg; administered to subjects with moderate or severe hepatic impairment.
Number of subjects: 0
Study 25136079 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 0
Study 25136079 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic technologies (optical coherence tomography)
Number of subjects: 0
Study 25136536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Korean white ginseng (KWG)
Number of subjects: 25
Study 25136689 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injections (5 weekly injections)
Number of subjects: 50
Study 25136689 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 25136951 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution using a port-a-catheter (CIport)
Number of subjects: 27
Study 25136951 — intervention group
Group type: COMPARATOR
Intervention: Transpulmonary thermodilution using central venous access (CIcvc)
Number of subjects: 27
Study 25137424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis lesions
Number of subjects: 76
Study 25137424 — intervention group
Group type: COMPARATOR
Intervention: Endometrial tissue progesterone (P4) concentrations
Number of subjects: 76
Study 25137424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis lesions with contraceptive medication
Number of subjects: 76
Study 25137424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian lesions
Number of subjects: 76
Study 25137427 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy leading to remission (normal IGF-1)
Number of subjects: 42
Study 25137427 — intervention group
Group type: COMPARATOR
Intervention: Persistent active acromegaly (elevated IGF-1)
Number of subjects: 42
Study 25138249 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 135
Study 25138249 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 135
Study 25138680 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 0
Study 25139018 — intervention group
Group type: EXPERIMENTAL
Intervention: E7-specific CD8(+) T-cell responses
Number of subjects: 134
Study 25139018 — intervention group
Group type: EXPERIMENTAL
Intervention: E6-specific CD4(+) T-cell responses
Number of subjects: 134
Study 25139018 — intervention group
Group type: EXPERIMENTAL
Intervention: E6- and E7-specific CD8(+) T-cell responses
Number of subjects: 134
Study 25139018 — intervention group
Group type: EXPERIMENTAL
Intervention: E7-specific CD4(+) T-cell responses
Number of subjects: 134
Study 25139883 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese adolescents
Number of subjects: 40
Study 25139883 — intervention group
Group type: COMPARATOR
Intervention: Lean adolescents
Number of subjects: 40
Study 25139883 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (obese and lean)
Number of subjects: 40
Study 25139963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN alfa-2a (180 µg/week) and RBV (1000-1200 mg/day) for 12 weeks followed by peg-IFN/RBV for 32-56 weeks according to virological response at week 8
Number of subjects: 69
Study 25139963 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFN/RBV
Number of subjects: 69
Study 25141098 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 243
Study 25141098 — intervention group
Group type: EXPERIMENTAL
Intervention: African American spouses
Number of subjects: 243
Study 25141098 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-African Americans
Number of subjects: 243
Study 25141098 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouses
Number of subjects: 243
Study 25141112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (1470 ml) and mannitol (15% 200 ml) during cardiopulmonary bypass
Number of subjects: 10
Study 25141184 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted melanoma screening intervention
Number of subjects: 3923
Study 25141184 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to dermatologists
Number of subjects: 3923
Study 25141184 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing a dermatologist's name
Number of subjects: 3923
Study 25141184 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay before consulting a dermatologist
Number of subjects: 3923
Study 25141237 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal test in patients with T2D
Number of subjects: 50
Study 25141820 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural recovery from a gambling problem
Number of subjects: 0
Study 25141820 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of a gambling problem with intermediate care intervention
Number of subjects: 0
Study 25141820 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapses or care recourse
Number of subjects: 0
Study 25141820 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment through structured clinical interview and self-assessment questionnaires
Number of subjects: 0
Study 25141820 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment from various gambling places and care centers
Number of subjects: 0
Study 25142258 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-75 administered Q3Wk at doses escalated from 0.3 to 4.5 mg/kg
Number of subjects: 58
Study 25142258 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-75 administered weekly at doses of 0.3 or 0.6 mg/kg
Number of subjects: 58
Study 25142258 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-75 administered Q3Wk
Number of subjects: 58
Study 25142258 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-75 treatment
Number of subjects: 58
Study 25142258 — intervention group
Group type: COMPARATOR
Intervention: SGN-75 administration Q3Wk vs. weekly dosing
Number of subjects: 58
Study 25142320 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RBP4 levels in CAD patients
Number of subjects: 305
Study 25142320 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RBP4 levels in AMI and SA subgroups
Number of subjects: 305
Study 25142320 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for CAD presence
Number of subjects: 305
Study 25142320 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of variables with CAD severity
Number of subjects: 305
Study 25142320 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4 concentrations and number of coronary narrowed vessels
Number of subjects: 305
Study 25142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 25142486 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard ICS treatment)
Number of subjects: 0
Study 25142490 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25142735 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04937319 (glucokinase activator) at doses of 100 mg and 300 mg
Number of subjects: 0
Study 25142735 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04937319 (glucokinase activator)
Number of subjects: 0
Study 25142735 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 (metabolite of PF-04937319)
Number of subjects: 0
Study 25142770 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleepers (GS, n = 252) defined by PSQI < 5
Number of subjects: 500
Study 25142770 — intervention group
Group type: COMPARATOR
Intervention: Poor sleepers (PS, n = 248) defined by PSQI > 5
Number of subjects: 500
Study 25142770 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleepers (< 6 h), normal sleepers (> 6h to < 8 h), and long sleepers (> 8 h)
Number of subjects: 500
Study 25142770 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 500
Study 25143232 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex method using Luminex technology to detect antibodies against 32 synthetic biotinylated peptides comprising predicted neo-antigens.
Number of subjects: 1
Study 25143232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized rabbits
Number of subjects: 1
Study 25143374 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-element multiple micronutrient powder (MNP) administered daily for 5 months
Number of subjects: 178
Study 25143374 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nutrition, health, and hygiene education)
Number of subjects: 178
Study 25143487 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 400 to 1200 mg (phase 1)
Number of subjects: 33
Study 25143487 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg (phase 2)
Number of subjects: 33
Study 25144126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose intake (highest quintile)
Number of subjects: 223230
Study 25144126 — intervention group
Group type: COMPARATOR
Intervention: Fructose intake (lowest quintile)
Number of subjects: 223230
Study 25144817 — intervention group
Group type: EXPERIMENTAL
Intervention: LTLD at 50 mg/m2 with MLHT
Number of subjects: 29
Study 25145344 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR regimen (bendamustine 130 mg/m2 per day for 3 days, fludarabine, and rituximab)
Number of subjects: 56
Study 25145469 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin initiation support program
Number of subjects: 30
Study 25145469 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 25145775 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 2954
Study 25145775 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2954
Study 25145775 — intervention group
Group type: COMPARATOR
Intervention: Control (Japanese Encephalitis vaccine)
Number of subjects: 2954
Study 25146065 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 1000
Study 25146149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 114
Study 25146149 — intervention group
Group type: EXPERIMENTAL
Intervention: Purging disorder (PD)
Number of subjects: 114
Study 25146149 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 114
Study 25147039 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy (DA)
Number of subjects: 800
Study 25148012 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 40 mm Hg
Number of subjects: 6
Study 25148012 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 50 mm Hg
Number of subjects: 6
Study 25148012 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 60 mm Hg
Number of subjects: 6
Study 25148012 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to baseline respirator settings
Number of subjects: 6
Study 25148012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous drainage of cerebrospinal fluid (CSF)
Number of subjects: 6
Study 25148882 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal plasma choline concentration in preterm infants
Number of subjects: 162
Study 25148882 — intervention group
Group type: COMPARATOR
Intervention: Cord plasma choline concentration
Number of subjects: 162
Study 25148882 — intervention group
Group type: COMPARATOR
Intervention: Choline concentrations in parturients
Number of subjects: 162
Study 25148882 — intervention group
Group type: COMPARATOR
Intervention: Choline concentrations in non-pregnant women
Number of subjects: 162
Study 25148882 — intervention group
Group type: COMPARATOR
Intervention: Prenatal glucocorticoid treatment
Number of subjects: 162